{
    "doi": "https://doi.org/10.1182/blood.V112.11.436.436",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1286",
    "start_url_page_num": 1286,
    "is_scraped": "1",
    "article_title": "Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery ",
    "article_date": "November 16, 2008",
    "session_type": "Antithrombotic Therapy",
    "topics": [
        "gender",
        "orthopedic procedures",
        "orthopedics",
        "phase 3 clinical trials",
        "renal function",
        "rivaroxaban",
        "venous thromboembolism",
        "enoxaparin",
        "hemorrhage",
        "surgical procedures, operative"
    ],
    "author_names": [
        "Kenneth A. Bauer, MD",
        "Martin Homering",
        "Scott D. Berkowitz, MD, FACP"
    ],
    "author_affiliations": [
        [
            "Beth Israel Deaconess Medical Center, Boston, MA, USA"
        ],
        [
            "Bayer HealthCare AG, Wuppertal, Germany"
        ],
        [
            "Bayer HealthCare Pharmaceuticals, West Haven, CT, USA"
        ]
    ],
    "first_author_latitude": "42.33960629999999",
    "first_author_longitude": "-71.10498199999999",
    "abstract_text": "The RECORD program comprised four pivotal phase III trials comparing the oral direct Factor Xa inhibitor, rivaroxaban, with subcutaneous enoxaparin for the prevention of venous thromboembolism (VTE) after total hip and knee replacement (THR and TKR). A total of 12,729 patients were randomized to receive rivaroxaban 10 mg once daily (od) starting 6\u20138 hours after surgery, or enoxaparin 40 mg od (RECORD1\u20133) starting the evening before surgery, or 30 mg every 12 hours (RECORD4) starting 12\u201324 hours after surgery. In RECORD1, patients undergoing THR received extended prophylaxis for 31\u201339 days. In RECORD2, patients undergoing THR received rivaroxaban for 31\u201339 days, or enoxaparin for 12\u00b12 days followed by placebo up to 35 days. Patients undergoing TKR in RECORD3 and 4 received prophylaxis for 12\u00b12 days. In all four trials the rivaroxaban regimens showed superior efficacy to the enoxaparin regimens with no significant increase in bleeding. The RECORD1\u20134 pooled analysis showed that rivaroxaban was significantly superior to enoxaparin for the primary endpoint, symptomatic VTE and all-cause mortality (0.8% vs 1.6%, respectively; p75 yrs), weight (\u226470, >70\u201390, >90kg), gender, or renal function (CrCl >80, 50\u201380, 80 and 30 ml/min CrCl) groups studied. Similar trends were seen in the smaller subgroups of body weight extremes (>110 kg subgroup - total VTE: 5/100 [5.0%] vs 8/119 [6.7%], respectively; \u226450 kg subgroup - any bleeding: 12/147 [8.2%] vs 8/162 [4.9%], respectively). These results suggest that age, body weight, gender and renal function (>30 ml/min CrCl) have no clinically relevant effect on the efficacy or safety of rivaroxaban as thrombroprophylaxis following major orthopedic surgery.  Subgroup . Total VTE Odds ratio (rivaroxaban vs enoxaparin regimens) (95% CI . Major VTE Odds ratio (rivaroxaban vs enoxaparin regimens) (95% CI) . Any major or non-major bleeding Hazard ratio (rivaroxaban vs enoxaparin regimens) (95% CI) . *Because of study exclusion criteria, few patients had CrCl <30 ml/min, CI = confidence interval Age     <65 years 0.40 (0.28\u20130.55) 0.22 (0.10\u20130.44) 1.05 (0.86\u20131.29) 65\u201375 years 0.39 (0.29\u20130.52) 0.18 (0.08\u20130.34) 1.11 (0.90\u20131.38) >75 years 0.54 (0.36\u20130.81) 0.51 (0.21\u20131.15) 1.10 (0.79\u20131.52) Weight     \u226470kg 0.43 (0.31\u20130.60) 0.25 (0.11\u20130.52) 1.17 (0.91\u20131.51) >70\u201390kg 0.45 (0.34\u20130.59) 0.21 (0.11\u20130.39) 0.95 (0.77\u20131.17) >90kg 0.38 (0.25\u20130.57) 0.32 (0.13\u20130.69) 1.22 (0.95\u20131.58) Gender     Male 0.35 (0.25\u20130.48) 0.21 (0.10\u20130.40) 1.12 (0.93\u20131.36) Female 0.47 (0.37\u20130.59) 0.27 (0.16\u20130.45) 1.06 (0.87\u20131.28) CrCl (ml/min)     >80 0.35 (0.27\u20130.46) 0.22 (0.12\u20130.38) 1.12 (0.94\u20131.35) 50\u201380 0.60 (0.45\u20130.81) 0.30 (0.15\u20130.56) 0.99 (0.79\u20131.24) <50 *  0.32 (0.15\u20130.64) 0.23 (0.02\u20131.15) 1.07 (0.64 \u2013 1.79) Subgroup . Total VTE Odds ratio (rivaroxaban vs enoxaparin regimens) (95% CI . Major VTE Odds ratio (rivaroxaban vs enoxaparin regimens) (95% CI) . Any major or non-major bleeding Hazard ratio (rivaroxaban vs enoxaparin regimens) (95% CI) . *Because of study exclusion criteria, few patients had CrCl <30 ml/min, CI = confidence interval Age     <65 years 0.40 (0.28\u20130.55) 0.22 (0.10\u20130.44) 1.05 (0.86\u20131.29) 65\u201375 years 0.39 (0.29\u20130.52) 0.18 (0.08\u20130.34) 1.11 (0.90\u20131.38) >75 years 0.54 (0.36\u20130.81) 0.51 (0.21\u20131.15) 1.10 (0.79\u20131.52) Weight     \u226470kg 0.43 (0.31\u20130.60) 0.25 (0.11\u20130.52) 1.17 (0.91\u20131.51) >70\u201390kg 0.45 (0.34\u20130.59) 0.21 (0.11\u20130.39) 0.95 (0.77\u20131.17) >90kg 0.38 (0.25\u20130.57) 0.32 (0.13\u20130.69) 1.22 (0.95\u20131.58) Gender     Male 0.35 (0.25\u20130.48) 0.21 (0.10\u20130.40) 1.12 (0.93\u20131.36) Female 0.47 (0.37\u20130.59) 0.27 (0.16\u20130.45) 1.06 (0.87\u20131.28) CrCl (ml/min)     >80 0.35 (0.27\u20130.46) 0.22 (0.12\u20130.38) 1.12 (0.94\u20131.35) 50\u201380 0.60 (0.45\u20130.81) 0.30 (0.15\u20130.56) 0.99 (0.79\u20131.24) <50 *  0.32 (0.15\u20130.64) 0.23 (0.02\u20131.15) 1.07 (0.64 \u2013 1.79) View Large"
}